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Abstract
Purpose In 2007, a large goat-farming-associated Q fever
outbreak occurred in the Netherlands. Data on the clinical
outcome of Dutch Q fever patients are lacking. The current
advocated follow-up strategy includes serological follow-
up to detect evolution to chronic disease and cardiac
screening at baseline to identify and prophylactically treat
Q fever patients in case of valvulopathy. However, sero-
logical follow-up using commercially available tests is
complicated by the lack of validated cut-off values.
Furthermore, cardiac screening in the setting of a large
outbreak has not been implemented previously. Therefore,
we report here the clinical outcome, serological follow-up
and cardiac screening data of the Q fever patients of the
current ongoing outbreak.
Methods The implementation of a protocol including
clinical and serological follow-up at baseline and 3, 6 and
12 months after acute Q fever and screening echocardi-
ography at baseline.
Results Eighty-five patients with acute Q fever were
identified (male 62%, female 38%). An aspecific, flu-like
illness was the most common clinical presentation. Persis-
tent symptoms after acute Q fever were reported by 59% of
patients at 6 months and 30% at 12 months follow-up. We
observed a typical serological response to Coxiella burnetii
infection in both anti-phase I and anti-phase II IgG anti-
bodies, with an increase in antibody titres up to 3 months and
a subsequent decrease in the following 9 months. Screening
echocardiography was available for 66 (78%) out of 85 Q
fever patients. Cardiac valvulopathy was present in 39 (59%)
patients. None of the 85 patients developed chronic Q fever.
Conclusions Clinical, serological and echocardiographic
data of the current ongoing Dutch Q fever outbreak cohort
are presented. Screening echocardiography is no longer
part of the standard work-up of Q fever patients in the
Netherlands.
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Introduction
In late spring 2007, a large Q fever outbreak in the
Netherlands occurred in the province of Noord Brabant,
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with a distinct epidemic centre around the town of Herpen
[1]. Although no definitive source for the outbreak was
identified, the preceding increased abortion rate amongst
goats in the region suggested these ruminants as being the
most likely reservoir [2, 3].
Q fever is a ubiquitous zoonosis caused by the obligate
intracellular bacterium Coxiella burnetii. The clinical
manifestations of this acute infection are usually self-lim-
iting and range from a mild flu-like febrile illness to
atypical pneumonia and hepatitis [4]. Serological and
clinical follow-up after primary infection is recommended
because approximately 1–5% of patients will develop
chronic Q fever, endocarditis being the clinical manifes-
tation in 60–70% of cases [5]. Cardiac valve abnormalities,
vascular prosthesis, compromised immunity and pregnancy
constitute predisposing host factors for chronic Q fever [6].
Recently, screening echocardiography has been added to
the standard of care for Q fever patients [7, 8]. In daily
clinical practice, however, adequate follow-up of patients
after acute Q fever has practical difficulties. First, the
interpretation of serology obtained by commercially
available tests is hampered by incomplete knowledge of the
natural course of the antibody response to Coxiella burnetii
and the lack of validated cut-off values for chronic disease.
Second, minor cardiac valvulopathies are frequently
encountered in the general population, raising the question
whether, indeed, all patients with cardiac valve abnor-
malities should receive prolonged prophylactic antibiotic
treatment.
Faced with the aforementioned Q fever outbreak in the
Netherlands, a follow-up protocol was implemented,
including clinical and serological follow-up for a 1-year
period, and Q fever patients were offered a screening
echocardiography at baseline. The aim of this paper was to
report the clinical characteristics and outcome, serological
data and echocardiographic findings of the current ongoing
Q fever outbreak in the Netherlands.
Methods
Q fever case definition
A case of acute Q fever was defined as any inhabitant of the
outbreak cluster area who presented with one or more
compatible clinical symptoms (fever, fatigue, chills,
headache, myalgia, sweats, cough [4]) and the demon-
stration of infection with Coxiella burnetii, as evidenced
by: (1) a seroconversion or four-fold increase of antibody
titre using a Coxiella burnetii complement fixation test
(CFT) in samples taken at least 14 days apart, (2) the
presence of both anti-phase II IgM and anti-phase II IgG
antibodies in the Coxiella burnetii immunofluorescence
assay (IFA) with a 1:64 or greater dilution [1] or a positive
serum polymerase chain reaction (PCR). For patients
admitted to hospital and presenting with pneumonia, the
severity of disease was assessed using the pneumonia
severity index (PSI) [9].
A case of chronic Q fever is defined as any inhabitant of
the outbreak cluster area with a clinical entity compatible
with chronic Coxiella burnetii infection as described in the
literature by Raoult (endocarditis, vascular infection,
osteoarticular infection, chronic hepatitis, pregnancy), in
the presence of an anti-phase I IgG titre C800, for
C6 months after the initial day of illness [4, 10].
Follow-up protocol
The follow-up protocol consisted of a complete history and
physical examination at 6 and 12 months after the initial
day of illness, serological testing at baseline, followed by
testing after 3, 6 and 12 months after a referral to a car-
diologist for a single screening transthoracic echocardio-
gram. Data on symptoms were obtained by asking the
patient an open question on the presence of any complaints.
No structured questionnaire was used. As the Q fever
outbreak was identified retrospectively, data on presenting
symptoms at baseline were collected through the review of
all available medical records at the GP practice. Since this
concerned an observational study, all interventions had
been part of the standard care. Therefore, patients were
asked to co-operate and no specific ethical approval for this
study was sought.
Serology and polymerase chain reaction
Sera were tested for Coxiella burnetii antibodies using a
CFT (Institute Virion/Serion, GmbH, Wu¨rzburg, Germany),
testing only anti-phase II antibodies, and an IFA (Focus
Diagnostics, Cypress, CA, USA), assessing IgM and IgG
antibodies to both phase I and II antibodies. Sera taken at
baseline (T = 0) were also tested by PCR as described in
the literature [11]. The respective time-points for final
analysis were defined as follows: baseline (T = 0) is the
date of the first available serological results within
6 weeks after the first day of illness; serological results at
3 (T = 3), 6 (T = 6) and 12 months (T = 12) after the
first day of illness were included if blood samples were
drawn at these time-points, with a margin of plus or
minus 1 month.
Screening echocardiography
Structural cardiac abnormalities and valvular defects were
classified according to the American Society of Echocar-
diography (ASE) guidelines [12–15]. The ASE guidelines
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are a consensus statement of the American College of
Cardiology, the American Heart Association and the
European Society of Cardiology. These guidelines provide
a framework for the standardised assessment of the severity
of valvular regurgitation and stenosis, using well-defined
structural, Doppler and quantitative echocardiographic
parameters. Major (or clinically significant) valvulopathies
are defined as moderate and severe regurgitation or stenosis
of the mitral and/or aortic valve. Minor valvulopathies are
defined as trace or mild regurgitation or stenosis of the
mitral and/or aortic valve, a bicuspid aortic valve and
mitral valve prolapse without significant accompanying
stenosis or regurgitation. Data to calculate percentages
were analysed using Microsoft Excel 7.0 and SPSS 17.0.
GraphPad Prism 4.0 was used to generate Fig. 1.
Results
The Herpen Q fever outbreak cohort
A total of 85 patients with acute Q fever were identified in
the outbreak cluster. The patient characteristics are given in
Table 1. The male-to-female ratio was 1.7. None of the
female patients was pregnant. Co-morbidity was present in
26 patients (31%). Six patients had a known risk factor for
Fig. 1 One-year serological
follow-up of patients with acute
Q fever by complement fixation
test (CFT; antibodies to phase
II) and immunofluorescence
assay (IFA; IgG- and IgM-
antibodies to phase I and phase
II). The horizontal bars
represent the mean
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developing chronic Q fever: four patients with previously
documented significant cardiac valvulopathies, one patient
using long-term high-dose corticosteroids for idiopathic
thrombocytopenic purpura and one patient with an aortic
vascular prosthesis. Complete baseline and follow-up data
on symptoms and physical examinations were available for
all patients and are given in Table 2.
An aspecific, flu-like illness was the most common
clinical presentation. All patients who were admitted to
hospital (8 female, 16 male) presented with (atypical)
pneumonia and 83% of these patients had a PSI of class I or
class II, representing a low disease severity [9]. At
6 months follow-up, more than half of all Q fever patients
had persistent symptoms, fatigue being the most prevalent
complaint. At one year, reports of persistent symptoms had
roughly halved. Twenty-six percent of patients still
reporting fatigue which they attributed to their acute Q
fever episode. None of the 85 patients had developed
chronic Q fever at the 1-year follow-up point. One male
patient died of a myocardial infarction at 8 months follow-
up, unrelated to Q fever.
Serology
Serological data were available at baseline (68%), at
3 months follow-up (49%), at 6 months follow-up (81%)
and at 12 months follow-up (75%). The results are shown
in Fig. 1. CFT and IFA showed similar profiles, but at a
different titre level. The numbers of patients with an anti-
phase I IgG titre equal to or more than 800 (suggesting
chronic disease) at the respective time-points were 7
(T = 0), 21 (T = 3), 13 (T = 6) and 2 (T = 12). PCR was
performed on 60 out of 85 first available sera. Seven of
these 60 patients (11.6%) had a positive PCR and negative
serology. All PCR-positive patients subsequently serocon-
verted after 3 months.
Echocardiography
Screening transthoracic echocardiography was available
for 66 (78%) out of 85 Q fever patients. The remaining 19
patients repeatedly failed to show up at their appointment
for a transthoracic echocardiogram. The results are shown
in Table 3.
Cardiac valvulopathy was present in 39 (59%) patients,
five of whom had a major or clinically significant (moderate
Table 1 Characteristics of the Q fever outbreak cohort (n = 85)
Male/female [n (%)] 53 (62)/32 (38)
Mean age [years (range)] 49 (18–80)
Co-morbidity [n (%)] 26 (31)
Cardiovascular 6 (7)
Pulmonary 3 (4)
Neurological 1 (1)
Rheumatological 4 (5)
Haematological 1 (1)
Depression 3 (4)
Diabetes 5 (6)
Other 3 (4)
Immunocompromised [n (%)] 1 (1)
Vascular graft [n (%)] 1 (1)
Antibiotic treatment [n (%)]
Doxycycline 5 (6)
Moxifloxacin 35 (41)
Beta-lactam antibiotic 32 (38)
Azithromycin 1 (1)
None 12 (14)
Mortality due to Q fever 0 (0)
Overall one-year mortality 1 (1)
Hospitalisation [n (%)] 24 (28)
Pneumonia severity index (PSI) of hospitalised patients
PSI class I 12 (50)
PSI class II 8 (33)
PSI class III 4 (17)
PSI class IV and class V 0 (0)
Intensive care treatment 0 (0)
Duration of hospitalisation (days, median) 4 (5)
Table 2 Clinical presentation and follow-up
T = 0 T = 6 T = 12
(n = 85) (n = 85) (n = 84)a
Symptoms (%)
Any symptoms 100 59 30
Fever 93 0 0
Fatigue 69 52 26
Headache 40 1 1
Cough 39 0 0
Myalgia 34 1 2
Sweats 32 6 6
Dyspnoea 24 19 5
Anorexia 17 0 0
Nausea 14 0 0
Arthralgia 11 1 2
Abdominal pain 11 0 0
Cognitive disturbance 0 4 1
Physical examination (%)
Cardiac murmur 5 8 7
Pulmonary crackles 12 0 0
Hepatosplenomegaly 2 0 0
a One patient died of a myocardial infarction, not related to Q fever,
at 8 months follow-up
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or severe) valvulopathy. Four of these five patients were
previously known to have a cardiac valvulopathy. One
patient had a bicuspid aortic valve associated with a mod-
erate aortic insufficiency. This anomaly was classified as a
clinically significant valvulopathy. The remaining 34 patients
had one or more minor cardiac valvular abnormalities.
Discussion
As expected, an aspecific, flu-like syndrome with or
without signs of respiratory tract infection was the main
clinical Q fever manifestation in this remarkably compliant
cohort of patients. However, chest radiography was only
performed in patients admitted to hospital, which could
underestimate the prevalence of pneumonia in patients
treated by their GP. Males were more likely to suffer from
symptomatic Q fever than females, which is a well-known
phenomenon and appears to be the result of the gender-
related expression of sex hormones [16].
Fatigue was noted by Q fever patients in 52% at
6 months and 26% at 1 year following primary infection.
Other research groups, using various questionnaires, have
reported a comparably high proportion of fatigued patients
[17–21]. However, fatigue levels in this outbreak cohort
are self-reported and a control group is lacking. Therefore,
these findings must be interpreted with extreme caution.
Further studies are needed to evaluate the long-term
symptoms and quality of life in Q fever patients in the
Netherlands.
Using a commercially available IFA, we observed a
typical serological response to Coxiella burnetii infection
with strikingly high levels of antibodies to both phase I and
phase II antibodies. This serological response was charac-
terised by an increase in antibody titres up to 3 months and
a subsequent decrease in the following 9 months. The anti-
phase I IgG kinetic, with a titre peak at 3 months, is dif-
ferent from the available literature on IFA serological
patterns in the follow-up of acute Q fever, which shows a
rather slow and gradual increase of anti-phase I IgG anti-
bodies [22, 23]. The high proportion of Q fever patients in
this cohort that received a beta-lactam antibiotic with no
efficacy against Coxiella burnetii (38%) or no treatment at
all (14%) could possibly account for this discrepancy. The
CFT and the IFA tests showed an identical serological
pattern over time. Therefore, both tests might be useful for
the follow-up of patients. Additional IFA testing should be
performed when the CFT titre is rising in order to observe
the balance between anti-phase I and anti-phase II IgG
antibodies.
Although at the various time-points there were patients
with an anti-phase I IgG antibody titre of 1,024 or more,
suggesting chronic disease, none of these patients devel-
oped a clinical picture compatible with chronic Q fever.
Furthermore, at follow-up, all of these patients showed a
spontaneous subsequent decline in anti-phase I IgG titres,
which, in the case of a possible chronic Q fever, is highly
unlikely, given the natural detrimental course of chronic
disease if left untreated.
For aiding in the diagnosis of chronic Q fever, we used
the well-established anti-phase I IgG antibody titre of C800
[10]. Unfortunately, this cut-off value is based on a single-
centre experience using a home-made IFA test. Additional
studies are urgently needed to compare both tests and to
give cut-off levels that can be used with commercially
available IFA tests.
Q fever endocarditis may develop in up to 39% of
patients with known pre-existing valvulopathy [24]. Even
minor cardiac valve abnormalities might be a risk factor for
Q fever endocarditis [7]. An active search for cardiac
valvular abnormalities and serological surveillance fol-
lowing acute Q fever have been advocated to identify
chronic Q fever in an early stage and to trigger prolonged
prophylactic antibiotic treatment in case of even minor
cardiac valvulopathy [7, 8, 25].
No cases of chronic Q fever were observed during the
follow-up, despite the high incidence of minor valvulopa-
thies found by screening echocardiography. Similar inci-
dences of minor cardiac valvular abnormalities in the
general population have been reported in large series [26,
27]. For example, the prevalence of ‘trace’ mitral valve
regurgitation is 40% and can, therefore, be considered to be
a physiological phenomenon without clinical importance
[12]. The prevalence of mitral valve prolapse and bicuspid
aortic valve is estimated to be 2–3% and circa 1%,
respectively [28, 29]. The absolute risk of developing
chronic Q fever for these minor valvulopathies remains
unknown. The limited number of patients in this study does
not allow to determine this risk, but it is clear that the
absolute risk, at least in the case of a minor mitral valve
insufficiency, is likely to be small enough to withhold
prolonged prophylactic antibiotic treatment and closely
monitor serology during the follow-up.
In the setting of the ongoing Q fever epidemic in the
Netherlands that currently encompasses more than 3,000
new Q fever patients, performing screening echocardiograms
Table 3 Cardiac valvulopathies in Q fever patients (n = 66)
Severity of valvulopathy (no. of patients)
Trace Mild Moderate Severe
Mitral valve regurgitation 23 9 2 1
Mitral valve stenosis 0 0 0 0
Aortic valve regurgitation 5 2 2 0
Aortic valve stenosis 0 1 0 0
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in all patients is costly [30]. Moreover, it is not likely that
such a screening will detect cardiac valve abnormalities
that, in turn, would influence clinical management.
Therefore, we currently perform only serological and
clinical follow-up after acute Q fever, omitting routine
screening echocardiography. In other words, in the context
of the large and continuous outbreak in the Netherlands, a
pragmatic approach has been adopted for patients without
known risk factors for chronic disease, consisting of close
serological monitoring for a period of 1 year (at 3, 6 and
12 months). Only when serological and/or clinical signs of
chronic disease appear is further investigation using PCR
and echocardiography undertaken. In patients with known,
pre-existing risk factors for chronic disease, including
cardiac valvulopathy, decisions regarding follow-up and
prophylactic antibiotic treatment are made in each indi-
vidual case by a multi-disciplinary team including a
medical microbiologist, infectiologist and cardiologist. We
realise that such a strategy can only be applied in countries
with a low background prevalence of cardiac valvulopa-
thies in the general population. Indeed, in India, due to the
high prevalence of rheumatic heart disease, Coxiella
burnetii is responsible for 14% of culture-negative endo-
carditis cases [31].
In conclusion, in the Dutch Q fever outbreak, an aspe-
cific febrile illness with or without respiratory tract
symptoms was the most common clinical presentation.
Fatigue was present in 52% of patients at 6 months and this
dropped to 26% at 1-year follow-up. Using a commercially
available IFA, we observed a typical serological response
to both phase I and phase II Coxiella burnetii antigens,
characterised by an increase in antibody titres up to
3 months and a subsequent decrease in the following
9 months. Screening echocardiography at baseline revealed
cardiac valve abnormalities in 59% of patients investi-
gated, with only 7.6% having a clinically significant val-
vulopathy. None of the patients progressed to chronic
disease. Baseline screening echocardiography is no longer
part of the standard work-up of Q fever patients the
Netherlands.
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